PolyLLM: polypharmacy side effect prediction via LLM-based SMILES encodings

PolyLLM:基于LLM的SMILES编码的多药联用副作用预测

阅读:2

Abstract

Polypharmacy, the concurrent use of multiple drugs, is a common approach to treating patients with complex diseases or multiple conditions. Although consuming a combination of drugs can be beneficial in some cases, it can lead to unintended drug-drug interactions (DDI) and increase the risk of adverse side effects. Predicting these adverse side effects using state-of-the-art models like Large Language Models (LLMs) can greatly assist clinicians. In this study, we assess the impact of using different LLMs to predict polypharmacy. First, the chemical structure of drugs is vectorized using several LLMs such as ChemBERTa, GPT, etc., and are then combined to obtain a single representation for each drug pair. The drug pair representation is then fed into two separate models including a Multilayer Perceptron (MLP) and a Graph Neural Network (GNN) to predict the side effects. Our experimental evaluations show that integrating the embeddings of Deepchem ChemBERTa with the GNN architecture yields more effective results than other methods. Additionally, we demonstrated that utilizing complex models like LLMs to predict polypharmacy side effects using only chemical structures of drugs can be highly effective, even without incorporating other entities such as proteins or cell lines, which is particularly advantageous in scenarios where these entities are not available.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。